{"id":"https://openalex.org/W4362536282","doi":"https://doi.org/10.1158/1541-7786.22514085.v1","title":"Supplementary Figure 3 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance","display_name":"Supplementary Figure 3 from Targeting NAD+ Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362536282","doi":"https://doi.org/10.1158/1541-7786.22514085.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1541-7786.22514085.v1","doi":"https://doi.org/10.1158/1541-7786.22514085.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1541-7786.22514085.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_3_from_Targeting_NAD_sup_sup_Biosynthesis_Overcomes_Panobinostat_and_Bortezomib-Induced_Malignant_Glioma_Resistance/22514085/1/files/39976575.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_3_from_Targeting_NAD_sup_sup_Biosynthesis_Overcomes_Panobinostat_and_Bortezomib-Induced_Malignant_Glioma_Resistance/22514085/1/files/39976575.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015468249","display_name":"Esther P. Jane","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Esther P. Jane","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060216832","display_name":"Daniel R. Premkumar","orcid":"https://orcid.org/0000-0001-6885-0632","observed_orcids":["https://orcid.org/0000-0001-6885-0632"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel R. Premkumar","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050237283","display_name":"Swetha Thambireddy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Swetha Thambireddy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017136932","display_name":"Brian J. Golbourn","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brian Golbourn","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056492340","display_name":"Sameer Agnihotri","orcid":"https://orcid.org/0000-0001-6584-3795","observed_orcids":["https://orcid.org/0000-0001-6584-3795"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sameer Agnihotri","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023614951","display_name":"Kelsey C. Bertrand","orcid":"https://orcid.org/0009-0001-1676-7746","observed_orcids":["https://orcid.org/0009-0001-1676-7746","https://orcid.org/0000-0001-6382-5411"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelsey C. Bertrand","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060494950","display_name":"Stephen C. Mack","orcid":"https://orcid.org/0000-0001-9620-4742","observed_orcids":["https://orcid.org/0000-0001-9620-4742"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Stephen C. Mack","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022345601","display_name":"Max I. Myers","orcid":"https://orcid.org/0009-0001-4981-8992","observed_orcids":["https://orcid.org/0009-0001-4981-8992"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Max I. Myers","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042570169","display_name":"Ansuman Chattopadhyay","orcid":"https://orcid.org/0000-0002-5412-3749","observed_orcids":["https://orcid.org/0000-0002-5412-3749"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ansuman Chattopadhyay","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101682555","display_name":"D. Lansing Taylor","orcid":"https://orcid.org/0000-0001-6947-1343","observed_orcids":["https://orcid.org/0000-0001-6947-1343"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Lansing Taylor","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-6947-1343","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051585662","display_name":"Mark E. Schurdak","orcid":"https://orcid.org/0000-0002-1146-3268","observed_orcids":["https://orcid.org/0000-0002-1146-3268"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark E. Schurdak","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087508311","display_name":"Andrew M. Stern","orcid":"https://orcid.org/0000-0002-8437-2957","observed_orcids":["https://orcid.org/0000-0002-8437-2957"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andrew M. Stern","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5080784534","display_name":"Ian F. Pollack","orcid":"https://orcid.org/0000-0003-1765-357X","observed_orcids":["https://orcid.org/0000-0003-1765-357X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ian F. Pollack","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1765-357X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.6460000276565552,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.6460000276565552,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.04619999974966049,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11051","display_name":"Sirtuins and Resveratrol in Medicine","score":0.04610000178217888,"subfield":{"id":"https://openalex.org/subfields/2717","display_name":"Geriatrics and Gerontology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nad-biosynthesis","display_name":"NAD biosynthesis","score":0.9950000047683716},{"id":"https://openalex.org/keywords/panobinostat","display_name":"panobinostat","score":0.8960000276565552},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":1.0},{"id":"https://openalex.org/keywords/high-grade-glioma","display_name":"high-grade glioma","score":0.9290000200271606},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.9660000205039978},{"id":"https://openalex.org/keywords/u87-cells","display_name":"U87 cells","score":0.8040000200271606},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6759999990463257},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.7239999771118164},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9399999976158142}],"concepts":[{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.9727921485900879},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.9484588503837585},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5902139544487},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4215809106826782},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.39774948358535767},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.3770027160644531},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.33169686794281006},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.262925922870636},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.1749345064163208},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10974639654159546},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0710514485836029},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1541-7786.22514085.v1","doi":"https://doi.org/10.1158/1541-7786.22514085.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1541-7786.22514085.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_3_from_Targeting_NAD_sup_sup_Biosynthesis_Overcomes_Panobinostat_and_Bortezomib-Induced_Malignant_Glioma_Resistance/22514085/1/files/39976575.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22514085","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_3_from_Targeting_NAD_sup_sup_Biosynthesis_Overcomes_Panobinostat_and_Bortezomib-Induced_Malignant_Glioma_Resistance/22514085","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1541-7786.22514085.v1","doi":"https://doi.org/10.1158/1541-7786.22514085.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1541-7786.22514085.v1","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_3_from_Targeting_NAD_sup_sup_Biosynthesis_Overcomes_Panobinostat_and_Bortezomib-Induced_Malignant_Glioma_Resistance/22514085/1/files/39976575.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4362536282.pdf","grobid_xml":"https://content.openalex.org/works/W4362536282.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2377458274","https://openalex.org/W2409439928","https://openalex.org/W2104965094","https://openalex.org/W2063424779","https://openalex.org/W3028919400","https://openalex.org/W3029266790","https://openalex.org/W2027348595","https://openalex.org/W2012850828","https://openalex.org/W2124503326","https://openalex.org/W1991948976"],"abstract_inverted_index":{"Supplemental":[0],"Figure":[1],"3.":[2],"Drug":[3],"naive":[4],"U87":[5],"or":[6,9],"panobinostat-resistant,":[7],"bortezomib-resistant,":[8],"panobinostat":[10,20],"and":[11],"bortezomib-resistant":[12],"(P":[13],"+":[14],"B)":[15],"cells":[16],"were":[17],"cotreated":[18],"with":[19],"(25":[21],"nmol/L)":[22,26],"plus":[23],"bortezomib":[24],"(2.5":[25],"for":[27],"24":[28],"h.":[29]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-10-10T00:00:00"}